{{Unreferenced|date=December 2009}}
{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 462090629
| IUPAC_name = (''S'')-1-[''p''-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-(isopropylamino)-2-propanol hydrochloride
| image = levobetaxolol_structure.svg
| image2 = levobetaxolol-fill.png

<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|CONS|levobetaxolol}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = C <!-- A / B / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S4 / S8 -->
| legal_UK = <!-- GSL / P / POM / CD -->
| legal_US = <!-- OTC / Rx-only -->
| legal_status =  
| routes_of_administration = topical (ophthalmic)

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life = 20 hours
| excretion =  

<!--Identifiers-->
| IUPHAR_ligand = 8035
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 93221-48-8
| ATC_prefix = none
| ATC_suffix =  
| ATC_supplemental =  
| PubChem = 60657
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 54669
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 75O9XHA4TU
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 59254
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1201274

<!--Chemical data-->
| C=18 | H=29 | N=1 | O=3 
| molecular_weight = 307.427 g/mol
| smiles = O(CCc1ccc(OC[C@@H](O)CNC(C)C)cc1)CC2CC2
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C18H29NO3/c1-14(2)19-11-17(20)13-22-18-7-5-15(6-8-18)9-10-21-12-16-3-4-16/h5-8,14,16-17,19-20H,3-4,9-13H2,1-2H3/t17-/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = NWIUTZDMDHAVTP-KRWDZBQOSA-N
}}
'''Levobetaxolol''' is a drug used to lower the [[Intraocular pressure|pressure in the eye]] in treating conditions such as [[glaucoma]].  It is typically marketed as a 0.5% [[Eye drop|ophthalmic]] solution of '''levobetaxolol hydrochloride''' under the [[trade name]] '''Betaxon'''.  Levobetaxolol is a [[Beta receptor|beta-adrenergic]] [[Receptor antagonist|receptor inhibitor]] ([[beta blocker]]).

==Effect==
Levobetaxolol inhibits the beta-1-adrenergic receptor.  When applied topically, it reduces intra-ocular pressure (IOP) by 16-23% depending on time of day and the individual.  It is indicated for IOP reduction in patients with open-angle glaucoma or ocular hypertension.  Levobetaxolol has fewer cardiovascular side effects than other beta blockers.

==Contraindications and side effects==
Levobetaxolol should not be used by people who have [[sinus bradycardia]], [[atrioventricular block]], cardiogenic shock, or overt cardiac failure.

The drug has been associated with [[bradycardia]] and [[hypertension]].

== End of File ==

{{Beta blockers}}
{{Antiglaucoma preparations and miotics}}

[[Category:Beta blockers]]
[[Category:Ethers]]
[[Category:Phenol ethers]]
[[Category:Alcohols]]
[[Category:Enantiopure drugs]]